Sanofi

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Christian Beil

Gary J Nabel

Seng H Cheng

Peter D Kwong

Joerg Thomas Regula

John R Mascola

Jochen Beninga

Zhi-Yong Yang

Lan Wu

Huawei Qiu

Gerhard Hessler

Tongqing Zhou

Ercole Rao

Christian Lange

Ronnie Rong Wei

Edward Seung

Wulf Dirk Leuschner

Cendrine Lemoine

Catherine Prades

Ling Xu

Carsten Corvey

Yunxiang Zhu

Jochen Kruip

William Harold Brondyk

Béatrice Cameron

Tarik Dabdoubi

Thomas Langer

Vincent Mikol

Mark Connors

Young Do Kwon

Timothy D Connors

Ingo Focken

Hongmei Zhao

Nicolas Baurin

Anke Steinmetz

Danxi Li

Jinghe Huang

Wulf-Dirk Leuschner

Joerg Birkenfeld

Katja Kroll

Yangde Chen

Catherine Devaud

Sandra Weil

Leila Sevigny

Dietmar Hoffmann

Zhen Xing

Maureen Magnay

Nadja Spindler

Soraya Hoelper

Tristan Magnay

Chantal Carrez

Marion Schneider

Peter Wonerow

Karl-Christian Engel

Mangaiarkarasi Asokan

Amarendra Pegu

Jennifer Jung

Marta Amaral

Jana Albrecht

Cédric Barriere

Stéphane Guerif

Marie-Cécile Wetzel

Garima Tiwari

Richard A Koup

Sevim Ozgur Bruderle

Ronnie Wei

Nicole A Doria-rose

Rao Ercole

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific binding proteins, methods, and uses thereof

Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

Multispecific binding proteins with mutant fab domains

The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific and/or trivalent binding proteins

Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.

Multispecific antibodies facilitating selective light chain pairing

Provided herein are bivalent, bispecific binding proteins that specifically bind to two different HIV-1 Env protein epitopes.

Bivalent, bispecific binding proteins for prevention or treatment of HIV infection

Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

PseudoFab-based multispecific binding proteins

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Multispecific binding molecules having specificity to dystroglycan and laminin-2

The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.

Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123

Growing community of inventors

Frankfurt am Main, Germany

Christian Beil